Literature DB >> 26231739

Metabolically programmed iron chelators.

Raymond J Bergeron1, Neelam Bharti2, James S McManis2, Jan Wiegand2.   

Abstract

Extensive structure activity relationship (SAR) studies focused on the desferrithiocin [n class="Chemical">DFT, (S)-4,5-dihydro-2-(3-hydroxy-2-pyridinyl)-4-methyl-4-thiazolecarboxylic acid] pharmacophore have led to three different DFT analogs being evaluated clinically for the treatment of iron overload diseases, for example, thalassemia. The SAR work revealed that the lipophilicity of a ligand, as determined by its partition between octanol and water, logP(app), could have a profound effect on the drug's iron clearing efficiency (ICE), organ distribution, and toxicity profile. While within a given structural family the more lipophilic a chelator the better the ICE, unfortunately, the more lipophilic ligands are often more toxic. Thus, a balance between lipophilicity, ICE, and toxicity must be achieved. In the current study, we introduce the concept of 'metabolically programmed' iron chelators, that is, highly lipophilic, orally absorbable, effective deferration agents which, once absorbed, are quickly converted to their nontoxic, hydrophilic counterparts.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Metabolically programmed iron chelators

Mesh:

Substances:

Year:  2015        PMID: 26231739      PMCID: PMC4608554          DOI: 10.1016/j.bmc.2015.06.059

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  68 in total

1.  Natural history of C282Y homozygotes for hemochromatosis.

Authors:  John P Wojcik; Mark R Speechley; Ann E Kertesz; Subrata Chakrabarti; Paul C Adams
Journal:  Can J Gastroenterol       Date:  2002-05       Impact factor: 3.522

2.  ICL670A: preclinical profile.

Authors:  Hanspeter Nick; Agnes Wong; Pierre Acklin; Bernard Faller; Yi Jin; René Lattmann; Thomas Sergejew; Suzanne Hauffe; Helmut Thomas; Hans Peter Schnebli
Journal:  Adv Exp Med Biol       Date:  2002       Impact factor: 2.622

3.  Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate.

Authors:  G J Dover; S Brusilow; D Samid
Journal:  N Engl J Med       Date:  1992-08-20       Impact factor: 91.245

Review 4.  Preclinical and clinical development of deferitrin, a novel, orally available iron chelator.

Authors:  Joanne M Donovan; Melissa Plone; Rafif Dagher; Mark Bree; Judith Marquis
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

5.  A comparative evaluation of iron clearance models.

Authors:  R J Bergeron; R R Streiff; J Wiegand; J R Vinson; G Luchetta; K M Evans; H Peter; H B Jenny
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

6.  Syntheses and biological activity of amamistatin B and analogs.

Authors:  Kelley A Fennell; Ute Möllmann; Marvin J Miller
Journal:  J Org Chem       Date:  2008-01-04       Impact factor: 4.354

7.  Impact of the 3,6,9-trioxadecyloxy group on desazadesferrithiocin analogue iron clearance and organ distribution.

Authors:  Raymond J Bergeron; Jan Wiegand; Neelam Bharti; Shailendra Singh; James R Rocca
Journal:  J Med Chem       Date:  2007-06-12       Impact factor: 7.446

8.  Desferrithiocin is an effective iron chelator in vivo and in vitro but ferrithiocin is toxic.

Authors:  E Baker; A Wong; H Peter; A Jacobs
Journal:  Br J Haematol       Date:  1992-07       Impact factor: 6.998

Review 9.  Enterobactin: an archetype for microbial iron transport.

Authors:  Kenneth N Raymond; Emily A Dertz; Sanggoo S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-24       Impact factor: 11.205

10.  Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium.

Authors:  Yuzhao Zhou; Vishal S Vaidya; Ronald P Brown; Jun Zhang; Barry A Rosenzweig; Karol L Thompson; Terry J Miller; Joseph V Bonventre; Peter L Goering
Journal:  Toxicol Sci       Date:  2007-10-13       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.